Evidence map›Paper›PMID 30012132›Full record

ArticleBMC medicine2018

The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.

Alessia Melegaro, Valentina Marziano, Emanuele Del Fava, Piero Poletti, Marcello Tirani, Caterina Rizzo, Stefano Merler

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Spatiotemporal Epidemiology of Varicella in Chongqing, China, 2014-2018.International journal of environmental research and public health · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alessia MelegaroDepartment of Social and Political Sciences, Bocconi University, Milano, Italy. alessia.melegaro@unibocconi.it.ORCID 0000-0003-2221-8898
Valentina MarzianoCenter for Information and Communication Technology, Bruno Kessler Foundation, Trento, Italy.
Emanuele Del FavaCarlo F. Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milano, Italy.
Piero PolettiCenter for Information and Communication Technology, Bruno Kessler Foundation, Trento, Italy.
Marcello TiraniDepartment of Hygiene and Preventive Medicine, ATS, Bergamo, Italy.
Caterina RizzoDepartment of Infectious Disease, Istituto Superiore di Sanità, Roma, Italy.
Stefano MerlerCenter for Information and Communication Technology, Bruno Kessler Foundation, Trento, Italy.
Fondazione Bruno Kessler · ITBocconi University · ITIstituto Superiore di Sanità · IT

Funding

European Research Council 283955FP7 Ideas: European Research Council () 283955Medical Research Council G0601022Medical Research Council G9901400
6 · The paper itself

Abstract

backgroundThe present study aims to evaluate the cost-effectiveness of the newly introduced varicella and herpes zoster (HZ) vaccination programmes in Italy. The appropriateness of the introduction of the varicella vaccine is highly debated because of concerns about the consequences on HZ epidemiology and the expected increase in the number of severe cases in case of suboptimal coverage levels.

methodsWe performed a cost-utility analysis based on a stochastic individual-based model that considers realistic demographic processes and two different underlying mechanisms of exogenous boosting (temporary and progressive immunity). Routine varicella vaccination is given with a two-dose schedule (15 months, 5-6 years). The HZ vaccine is offered to the elderly (65 years), either alone or in combination with an initial catch-up campaign (66-75 years). The main outcome measures are averted cases and deaths, costs per quality-adjusted life years gained, incremental cost-effectiveness ratios, and net monetary benefits associated with the different vaccination policies.

resultsDemographic processes have contributed to shaping varicella and HZ epidemiology over the years, decreasing varicella circulation and increasing the incidence of HZ. The recent introduction of varicella vaccination in Italy is expected to produce an enduring reduction in varicella incidence and, indirectly, a further increase of HZ incidence in the first decades, followed by a significant reduction in the long term. However, the concurrent introduction of routine HZ vaccination at 65 years of age is expected to mitigate this increase and, in the longer run, to reduce HZ burden to its minimum. From an economic perspective, all the considered policies are cost-effective, with the exception of varicella vaccination alone when considering a time horizon of 50 years. These results are robust to parameter uncertainties, to the two different hypotheses on the mechanism driving exogenous boosting, and to different demographic projection scenarios.

conclusionsThe recent introduction of a combined varicella and HZ vaccination programme in Italy will produce significant reductions in the burden of both diseases and is found to be a cost-effective policy. This programme will counterbalance the increasing trend of zoster incidence purely due to demographic processes.

Indexed as

AgedChickenpox VaccineCost-Benefit AnalysisFemaleHerpes ZosterHumansItalyMaleChickenpox VaccineChickenpoxCost-effectivenessDemographyHerpes zosterImmunisationIndividual-based modelsItalyModellingShinglesVaccinationVaricella

Identifiers

PMID30012132
PMCPMC6048801
OpenAlexW2871208259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.